Merck and Moderna said their investigational personalized mRNA therapy, intismeran autogene, met both its primary endpoint and a key secondary endpoint in a Phase 3 trial when given with KEYTRUDA after surgery for high-risk melanoma. The companies described the result as the first positive Phase 3 readout for an individualized neoantigen therapy and for an mRNA-based cancer treatment, and the first late-stage study to show a clinically meaningful improvement over KEYTRUDA alone in the adjuvant melanoma setting.
Continue reading
The rest of this article is for AI News Blitz readers. Choose an option below to keep reading.
Already purchased? Sign in✓ Signed in — this article isn’t included in your current plan.
Unlocking the full article...
Contact us
Questions, corrections, or ideas? Send us a message here. We aim to reply by email within 24 hours.
Thank you. Your message has been sent. We aim to reply by email within 24 hours.Please enter your email address and a message.We could not send your message. Please try again in a little while.